Skip to main content

Table 4 Mean / median values of selected biomarkers, arranged by study

From: Associations between circulating obesity-related biomarkers and prognosis in female breast cancer survivors: a systematic review of observational data in women enrolled in lifestyle intervention trials

Authors (year) or study name, country

Patient population

Biomarker mean /median values

DIANA-2

 Berrino et al. (2005) [20]

Recurrent patients vs. non recurrent patients (all postmenopausal)

Mean values: Serum testosterone (0.52 vs. 0.38 ng/mL); Estradiol (8.06 vs. 5.52 pg/mL); Glucose (96 vs. 91 mg/dL). Data for insulin and SHBG were not reported

 Pasanisi et al. (2006) [21]

Patients with MetS vs. patients without MetS (all postmenopausal)

Mean ± SD: Serum testosterone (0.49 ± 0.15 vs. 0.41 ± 0.15 ng/mL); Glucose (103 vs. 90.8 mg/dL); Insulin (12.4 ± 6.58 vs. 7.4 ± 3.0 μUI/mL); SHBG (46.3 ± 28.13 vs. 67.8 ± 29.75 nmol/L), Triglycerides (155.6 vs. 99.7 mg/dL); HDL-c (49.8 vs. 56.7 mg/dL)

 Pasanisi et al. (2008) [22]

Recurrent patients vs. Non recurrent patients (all postmenopausal)

Mean ± SD: IGF-1 (188.2 ± 55.3 vs. 172.1 ± 60.3 ng/mL); PDGF (11.9 ± 5.1 vs. 9.4 ± 4.0 ng/mL); Fructosamine (329.1 ± 43.2 vs. 326.8 ± 48.7 μmol/L); CRP (1.97 ± 2.3 vs. 1.95 ± 2.9 mg/L)

DIANA-5

 Berrino et al. (2014) [23]

Patients with/without MetS (about 45% postmenopausal)

Means /ranges were not provided for any biomarker (glucose, HOMA-IR, triglycerides, HDL-c)

PACThe study

 Vasson et al. (2020) [24]

All patients (about 60% postmenopausal)

Mean ± SD: HDL-c (2.13 ± 1.28 mmol/L); Plasma testosterone (0.82 ± 0.36 nmol/L); CA 15–3 (18.1 ± 18.7 Ku/L)

WHEL study

 Emond et al. (2011) [25]

Comparison group, intervention group at baseline (all postmenopausal)

Median (IQR): Bioavailable estradiol (4.4 (2.8–7.1), 4.5 (2.8–7.1) pg/mL); Total estradiol (8.0 (5.0–12.0), 8.0 (5.0–12.0) pg/mL); Bioavailable testosterone (10.8 (7.4–16.2), 11.3 (7.8–15.2) ng/dL); Total testosterone (26.0 (19.3–37.8, 27.5 (20.8–37.3) ng/dL); SHBG (63.5 (44.0–91.5), 59.0 (43.3–90.0) nmol/L)

 Al-Delaimy et al. (2011) [26]

Cases (recurred) vs. Controls (non-recurred) (about 75–80% postmenopausal)

Mean ± SEM: Insulin (320 [16] vs. 354 [23] pg/mL); Leptin (23,521 (1573) vs. 23,117 (1369) pg/mL); Adiponectin (9301 (334) vs. 9449 (365) ng/mL) IGF-1 (114.1 (2.3) vs. 108.3 (2.1) ng/mL); IGFBP-1 (32.0 (1.5) vs. 33.7 (1.8) ng/mL); IGFBP-3 (4.17 (0.07) vs. 4.21 (0.07) μg/mL)

 Villaseñor et al. (2013) [27]

All patients (about 80% postmenopausal)

Median (IQR): Serum hsCRP (3.83 (0.67–4.24) mg/L)

  1. Abbreviations: CA 15–3 Cancer antigen 15–3, HDL-c High-density lipoprotein cholesterol, HOMA-IR Homeostatic model assessment for insulin resistance, hsCRP high sensitivity C-reactive protein, IGF-1 Insulin-like growth factor-1, IGFBP-3 Insulin-like growth factor-binding protein 3, IQR Interquartile range, MetS Metabolic syndrome, SHBG Sex hormone-binding globulin
  2. Reference values for women: Serum testosterone: 8–60 ng/dL; serum estradiol: premenopausal: 15–350 pg/mL, postmenopausal: < 10 pg/mL; SHBG: aged 20 - 49y: 24.6–122 nmol/L, aged > 49 y: 19.3–76.4 nmol/L; fasting glucose: 70 - 140 mg/dL); fasting insulin: 2.6–24.9 μUl/mL; serum CA 15–3: < 30 U/mL;. HDL-c: ≥ 50 mg/dL; triglycerides: < 150 mg/dL; IGF-1: aged 31–35 years: 59–279 ng/mL, 36–40 years: 54–258 ng/mL, 41–45 years: 49–240 ng/mL, 46–50 years: 44–227 ng/mL, 51–55 years: 40–217 ng/mL, 56–60 years: 37–208 ng/mL; serum CRP: < 8 mg/L. (reference values retrieved on September 14, 2022 from https://www.mayocliniclabs.com/test-catalog/overview)